Predictors of recurrent venous thromboembolism and bleeding on anticoagulation

•Recurrent VTE and bleeding complications are common in patients with malignancy•Multiple clinical risk factors for recurrent VTE and bleeding on anticoagulation have been described•Elevated tissue factor is predictive for recurrent VTE in malignancy and may be a novel biomarker

ABSTRACTThe impact of venous thromboembolism (VTE) in the cancer population remains substantial despite significant advances in detecting and treating thrombotic events. While there is extensive literature regarding predictors of first VTE event in cancer patients as well as a validated predictive score, less data exist regarding recurrent VTE in cancer cohorts and associated predictive variables. A similar paucity of data in regard to bleeding events in cancer patients receiving anticoagulation has been observed. This review article will highlight clinical risk factors as well as predictive biomarkers associated with recurrent VTE and bleeding in cancer patients receiving therapeutic anticoagulation. Predictive risk assessment models for cancer-associated recurrent VTE and bleeding are also discussed.